aTyr Pharma (NASDAQ:ATYR – Get Free Report) is anticipated to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect aTyr Pharma to post earnings of ($4.00) per share and revenue of $2.50 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.
aTyr Pharma (NASDAQ:ATYR – Get Free Report) last released its earnings results on Friday, August 7th. The company reported ($4.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.86) by $0.46. On average, analysts expect aTyr Pharma to post ($17.80) EPS for the current fiscal year and ($18.80) EPS for the next fiscal year.
aTyr Pharma Stock Up 27.3%
Shares of NASDAQ:ATYR opened at $6.29 on Tuesday. The firm has a fifty day moving average of $12.94 and a two-hundred day moving average of $24.03. The firm has a market capitalization of $15.42 million, a P/E ratio of -0.25 and a beta of 0.91. aTyr Pharma has a 12-month low of $4.07 and a 12-month high of $44.40.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on the stock. Weiss Ratings downgraded shares of aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 16th. Wall Street Zen raised aTyr Pharma to a “hold” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.
View Our Latest Analysis on aTyr Pharma
About aTyr Pharma
aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.
aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.
Further Reading
- Five stocks we like better than aTyr Pharma
- AST SpaceMobile’s Brazil Breakthrough Could Set the Stage for a Q3 Stock Rebound
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
